Category: Money tips Release Date: 2007-06-24
Source: Guotai Junan Research
39 Medical Group for the 39 most high-quality assets, a leading enterprise of Chinese medicine, with a huge brand and sales channel edge. As a debt settlement concept first unit, 39 Group's debt settlement and restructuring have been carried out in an orderly manner, Shangshiliange hope that 39 high-quality medical asset growth of Chinese medicine in which drug strength. At present, the acquisition of 39 medical Shangshiliange ongoing, with the acquisition of the expected increase, is expected to make 39 of Chinese medicine in share reform program, to surprise investors. The secondary market, as the reform does not share the potential of species, the active involvement of incremental funding, hoped for a pulled blowout of the market, cause for concern.
Last week, the market hot spots are concentrated into the A-share market for the first time two cases on the market, and conformation, "Baosteel's acquisition of Handan Iron and Steel", the transaction object G Handan Iron and Steel rose 70 percent in six trading days, Handan Iron & Steel warrants rose more than 200%, greatly stimulated the market nerves, accompanied by 600018G listed on the Hong Kong as a whole is approaching, and the structure, the overall market, raised placards of these tradable market's hottest topics this week to storm the marketplace. 000,999 39 medicine, the central enterprises restructuring of the secondary market for the first case of mergers and acquisitions and overall listing of the Group Shangshiliange soon can rival?
Shangshiliange 39 traditional Chinese medicine, when the acquisition is only May, there was some G China and Thailand, Shuanghui development, Zoomlion companies such as M & A matters, which indicates that the tide has been flowing into the M & A-tradable shares of listed companies, the era . At present, worthy of our attention is that of an M & A trend in the restructuring of the Group of 39 in the face of M & A expected.
39 medicine had issued an announcement of this year, saying that 39 groups are in contact with the three strategic investors, the three companies are the real group, Fosun Group, Singapore's Temasek. So far, recovery groups and Temasek have decided to withdraw from bidding, the real group is most likely to become re-entered the 39 companies, the real medicine side also frankly stated Lui Ming, chairman of the matter is indeed under way.
SIIC Medical Group has been struggling to integrate its business, its Shangshiliange is built on a solid pharmaceutical industry groups an important platform for the acquisition of 39 on the real medicine is an excellent opportunity for bigger and stronger. On the real Group's pharmaceutical industry is slowly injected into Shangshilianhe, Shangshilianhe soon changed its name to the real medicine. Shangshiliange current medical structure is rather clear, the main division is divided into traditional Chinese medicine, chemical medicine department, biopharmaceuticals and medical devices business unit division, which accounted for TCM Division about 70% share.
The general view of potential investors, the real intention is to restructure 39 39 39 Medicine's core assets. 39 Chinese medicine as a domestic medicine industry leading enterprises, brings together the best assets of the Group of 39, its brand famous, only the "999" brand valuation of intangible assets on more than 8.3 billion yuan, ranking top pharmaceutical industry. The real group took a fancy to 39 advantage of the field of medicine in traditional Chinese medicine, news that the real money will be 30 billion injection of 39 packages of medicine, which 39 of tremendous help revive traditional Chinese medicine, Chinese medicine Shangshiliange is also expected to help 39 the pharmaceutical industry to consolidate, seeking listing of its pharmaceutical industry as a whole.
SASAC's debt restructuring plan under the leadership of April 29, 2006 39 Medical announcement that 39 groups are currently under the leadership of the State-assets, debt restructuring, the restructuring of the parties had completely resolved in the restructuring of the Group of 39 and associated Medical financing occupying 39 square reach a consensus. In part by strategic investors to raise cash to return, some 39 groups using the assets to repay the loan repayment method. The end of 2006 efforts to complete the debt restructuring of assets, and comprehensive settlement of the amount of funds used.
At present, 39 development of procedures for the transfer of ownership transfer of shares has been completed, 39 items biochemical transfer of shares also received a State-owned Assets Supervision and Administration Commission approval. 39 medicine, said the successful sale of two shares of listed companies, will directly improve the preservation rate debt, significantly reduce the Group's assets, 39 debt restructuring difficult. Medicine's 39 other businesses, as well as shares of company's business will be further disposed of a lower level of profitability of pharmaceutical distribution business would be spun off, etc., holding the number of subsidiaries will be reduced to 10 nearly 60 more than the basic from the various participations exit.
The completion of the reorganization, the company will mainly produce and sell drugs to retain business, the company will benefit from the Group acquired a small amount of high-quality pharmaceutical production business. Chinese medicine in the 39 main business income, the proportion of the pharmaceutical manufacturing operations will be from 52.6% to 85.28%, to concentrate on developing core business will enable the operation of 39 medical ability to be restored to enhance performance.
In 2005, the company realized main business income of 2.969 billion yuan, net profit of 120 million, respectively, over the same period last year 20.62% and 116.64%. Companies focused on varieties of 999 Ganmaoling, are days of pills, Shenfu, 39 stomach Thailand, Pi Yan Ping Deng Jun achieve rapid growth, with an average growth rate of 3 6%. Speed up the introduction of new products and R & D project will also bring up the company momentum.
Blowout worth looking forward to continuing pulled up in the secondary market, affected by the recent reorganization and acquisition and other obscure the impact of good news, 39 out of unilateral upward trend in medicine today, has hit a new high this year, because of its standing as a secondary market for re-acquisition of the central section a case, the market image and the trend is bound to become a model for the future, and from the recent turnover of view, deeper involvement of the main funding, and carries the possibility of continued breakthroughs in greater focus. Xu Bin
